No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union...
Gespeichert in:
| Veröffentlicht in: | Open medicine (Warsaw, Poland) Poland), 2021-09, Vol.16 (1), p.1403-1414 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1414 |
|---|---|
| container_issue | 1 |
| container_start_page | 1403 |
| container_title | Open medicine (Warsaw, Poland) |
| container_volume | 16 |
| creator | Zheng, Shaoping Chen, Qiaosen Jiang, Hongbo Guo, Chunxia Luo, Jinzhuo Li, Sumeng Wang, Hua Li, Huadong Zheng, Xin Weng, Zhihong |
| description | There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement. |
| doi_str_mv | 10.1515/med-2021-0361 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_journals_2583623613</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5417170dbca341d691b37fd4420b6f22</doaj_id><sourcerecordid>2583623613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-729bef59a718684278408f04f4bd71c72e6332fa0a1af577ea3d6b0592f195f13</originalsourceid><addsrcrecordid>eNqNkc2LFDEQxRtR3GXdo_cGL4L0mspnB0SQ1tWRxb2o15DurowZepI16R7Z_96MM6yueBACKZJfPV7Vq6qnQC5AgHi5xbGhhEJDmIQH1SllGhrBJXv4R31Snee8IYSAYEor8rg6YVyC1CBPq4-fYp39OnjnBxvmuseAzs91dPU2jpjsjM0YM9Y7P9utD3VXx1Bn3GHCurv-unrbgK4HmzE_qR45O2U8P95n1ZfLd5-7D83V9ftV9-aqGQTA3Ciqe3RCWwWtbDlVLSetI9zxflQwKIqSMeossWCdUAotG2VPhKYOtHDAzqrVQXeMdmNukt_adGui9ebXQ0xrY9PshwmN4KBAkbEfLOMwlpF7ptzIOSW9dJQWrdcHrZulL8scMMzJTvdE7_8E_82s4860XGgNvAg8Pwqk-H3BPJutzwNOkw0Yl2yoaAmhkgEp6LO_0E1cUiir2lNM0pIhK1RzoIYUc07o7swAMfvQTXFj9qGbfeiFf3Hgf2AfXR48hgHvekrqioDmwEtF9x7a_6e7EvnsY-jiEubS-urYaqcZ04jrtNyW4vcU_zQI5XDC2E_Zl87B</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583623613</pqid></control><display><type>article</type><title>No significant benefit of moderate-dose vitamin C on severe COVID-19 cases</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Walter De Gruyter: Open Access Journals</source><source>PubMed Central</source><creator>Zheng, Shaoping ; Chen, Qiaosen ; Jiang, Hongbo ; Guo, Chunxia ; Luo, Jinzhuo ; Li, Sumeng ; Wang, Hua ; Li, Huadong ; Zheng, Xin ; Weng, Zhihong</creator><creatorcontrib>Zheng, Shaoping ; Chen, Qiaosen ; Jiang, Hongbo ; Guo, Chunxia ; Luo, Jinzhuo ; Li, Sumeng ; Wang, Hua ; Li, Huadong ; Zheng, Xin ; Weng, Zhihong</creatorcontrib><description>There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement.</description><identifier>ISSN: 2391-5463</identifier><identifier>EISSN: 2391-5463</identifier><identifier>DOI: 10.1515/med-2021-0361</identifier><identifier>PMID: 34616916</identifier><language>eng</language><publisher>WARSAW: De Gruyter</publisher><subject>Coronaviruses ; COVID-19 ; General & Internal Medicine ; Infectious diseases ; Life Sciences & Biomedicine ; Medicine, General & Internal ; SARS-Cov-2 ; Science & Technology ; Vitamin C</subject><ispartof>Open medicine (Warsaw, Poland), 2021-09, Vol.16 (1), p.1403-1414</ispartof><rights>2021. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Shaoping Zheng ., published by De Gruyter 2021 Shaoping Zheng et al., published by De Gruyter</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>11</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000701941400020</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c511t-729bef59a718684278408f04f4bd71c72e6332fa0a1af577ea3d6b0592f195f13</citedby><cites>FETCH-LOGICAL-c511t-729bef59a718684278408f04f4bd71c72e6332fa0a1af577ea3d6b0592f195f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459914/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459914/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27928,27929,53795,53797,67162,68946</link.rule.ids></links><search><creatorcontrib>Zheng, Shaoping</creatorcontrib><creatorcontrib>Chen, Qiaosen</creatorcontrib><creatorcontrib>Jiang, Hongbo</creatorcontrib><creatorcontrib>Guo, Chunxia</creatorcontrib><creatorcontrib>Luo, Jinzhuo</creatorcontrib><creatorcontrib>Li, Sumeng</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Li, Huadong</creatorcontrib><creatorcontrib>Zheng, Xin</creatorcontrib><creatorcontrib>Weng, Zhihong</creatorcontrib><title>No significant benefit of moderate-dose vitamin C on severe COVID-19 cases</title><title>Open medicine (Warsaw, Poland)</title><addtitle>OPEN MED-WARSAW</addtitle><description>There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>General & Internal Medicine</subject><subject>Infectious diseases</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine, General & Internal</subject><subject>SARS-Cov-2</subject><subject>Science & Technology</subject><subject>Vitamin C</subject><issn>2391-5463</issn><issn>2391-5463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DOA</sourceid><recordid>eNqNkc2LFDEQxRtR3GXdo_cGL4L0mspnB0SQ1tWRxb2o15DurowZepI16R7Z_96MM6yueBACKZJfPV7Vq6qnQC5AgHi5xbGhhEJDmIQH1SllGhrBJXv4R31Snee8IYSAYEor8rg6YVyC1CBPq4-fYp39OnjnBxvmuseAzs91dPU2jpjsjM0YM9Y7P9utD3VXx1Bn3GHCurv-unrbgK4HmzE_qR45O2U8P95n1ZfLd5-7D83V9ftV9-aqGQTA3Ciqe3RCWwWtbDlVLSetI9zxflQwKIqSMeossWCdUAotG2VPhKYOtHDAzqrVQXeMdmNukt_adGui9ebXQ0xrY9PshwmN4KBAkbEfLOMwlpF7ptzIOSW9dJQWrdcHrZulL8scMMzJTvdE7_8E_82s4860XGgNvAg8Pwqk-H3BPJutzwNOkw0Yl2yoaAmhkgEp6LO_0E1cUiir2lNM0pIhK1RzoIYUc07o7swAMfvQTXFj9qGbfeiFf3Hgf2AfXR48hgHvekrqioDmwEtF9x7a_6e7EvnsY-jiEubS-urYaqcZ04jrtNyW4vcU_zQI5XDC2E_Zl87B</recordid><startdate>20210922</startdate><enddate>20210922</enddate><creator>Zheng, Shaoping</creator><creator>Chen, Qiaosen</creator><creator>Jiang, Hongbo</creator><creator>Guo, Chunxia</creator><creator>Luo, Jinzhuo</creator><creator>Li, Sumeng</creator><creator>Wang, Hua</creator><creator>Li, Huadong</creator><creator>Zheng, Xin</creator><creator>Weng, Zhihong</creator><general>De Gruyter</general><general>Walter de Gruyter</general><general>Walter de Gruyter GmbH</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210922</creationdate><title>No significant benefit of moderate-dose vitamin C on severe COVID-19 cases</title><author>Zheng, Shaoping ; Chen, Qiaosen ; Jiang, Hongbo ; Guo, Chunxia ; Luo, Jinzhuo ; Li, Sumeng ; Wang, Hua ; Li, Huadong ; Zheng, Xin ; Weng, Zhihong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-729bef59a718684278408f04f4bd71c72e6332fa0a1af577ea3d6b0592f195f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>General & Internal Medicine</topic><topic>Infectious diseases</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine, General & Internal</topic><topic>SARS-Cov-2</topic><topic>Science & Technology</topic><topic>Vitamin C</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Shaoping</creatorcontrib><creatorcontrib>Chen, Qiaosen</creatorcontrib><creatorcontrib>Jiang, Hongbo</creatorcontrib><creatorcontrib>Guo, Chunxia</creatorcontrib><creatorcontrib>Luo, Jinzhuo</creatorcontrib><creatorcontrib>Li, Sumeng</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Li, Huadong</creatorcontrib><creatorcontrib>Zheng, Xin</creatorcontrib><creatorcontrib>Weng, Zhihong</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Open medicine (Warsaw, Poland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Shaoping</au><au>Chen, Qiaosen</au><au>Jiang, Hongbo</au><au>Guo, Chunxia</au><au>Luo, Jinzhuo</au><au>Li, Sumeng</au><au>Wang, Hua</au><au>Li, Huadong</au><au>Zheng, Xin</au><au>Weng, Zhihong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No significant benefit of moderate-dose vitamin C on severe COVID-19 cases</atitle><jtitle>Open medicine (Warsaw, Poland)</jtitle><stitle>OPEN MED-WARSAW</stitle><date>2021-09-22</date><risdate>2021</risdate><volume>16</volume><issue>1</issue><spage>1403</spage><epage>1414</epage><pages>1403-1414</pages><issn>2391-5463</issn><eissn>2391-5463</eissn><abstract>There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement.</abstract><cop>WARSAW</cop><pub>De Gruyter</pub><pmid>34616916</pmid><doi>10.1515/med-2021-0361</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2391-5463 |
| ispartof | Open medicine (Warsaw, Poland), 2021-09, Vol.16 (1), p.1403-1414 |
| issn | 2391-5463 2391-5463 |
| language | eng |
| recordid | cdi_proquest_journals_2583623613 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Walter De Gruyter: Open Access Journals; PubMed Central |
| subjects | Coronaviruses COVID-19 General & Internal Medicine Infectious diseases Life Sciences & Biomedicine Medicine, General & Internal SARS-Cov-2 Science & Technology Vitamin C |
| title | No significant benefit of moderate-dose vitamin C on severe COVID-19 cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T00%3A52%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20significant%20benefit%20of%20moderate-dose%20vitamin%20C%20on%20severe%20COVID-19%20cases&rft.jtitle=Open%20medicine%20(Warsaw,%20Poland)&rft.au=Zheng,%20Shaoping&rft.date=2021-09-22&rft.volume=16&rft.issue=1&rft.spage=1403&rft.epage=1414&rft.pages=1403-1414&rft.issn=2391-5463&rft.eissn=2391-5463&rft_id=info:doi/10.1515/med-2021-0361&rft_dat=%3Cproquest_webof%3E2583623613%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2583623613&rft_id=info:pmid/34616916&rft_doaj_id=oai_doaj_org_article_5417170dbca341d691b37fd4420b6f22&rfr_iscdi=true |